This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamamoto, K.
Right arrow Articles by Arai, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamamoto, K.
Right arrow Articles by Arai, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1908-1910, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1908-1910.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of Moxifloxacin and Other Fluoroquinolones against Mycoplasma pneumoniae

Kumiko Hamamoto, Takashi Shimizu, Naoyuki Fujimoto, Ye Zhang, and Sumio Arai*

Department of Bacteriology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan

Received 27 November 2000/Returned for modification 5 January 2001/Accepted 13 March 2001

A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC50 and MBC50) and 0.3 µg/ml (MIC90 and MBC90) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.

* Corresponding author. Mailing address: Department of Bacteriology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. Phone: 0942 31 7548. Fax: 0942 31 0343. E-mail: sumiyuku{at}mx2.tiki.ne.jp.

Antimicrobial Agents and Chemotherapy, June 2001, p. 1908-1910, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1908-1910.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hamasuna, R., Osada, Y., Jensen, J. S. (2005). Antibiotic Susceptibility Testing of Mycoplasma genitalium by TaqMan 5' Nuclease Real-Time PCR. Antimicrob. Agents Chemother. 49: 4993-4998 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 3973-3975 [Abstract] [Full Text]  
  • Duffy, L. B., Crabb, D. M., Bing, X., Waites, K. B. (2003). Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 52: 527-528 [Full Text]  
  • Waites, K. B., Crabb, D. M., Bing, X., Duffy, L. B. (2003). In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 161-165 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»